Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Heider

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Vaccines|August 29, 2024
Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients-A Tailored Approach Based on SARS-CoV-2 Vaccine ResponseKrischan Braitsch, Samuel D Jeske, Jacob Stroh, et al.
Molecular Cell|February 11, 2021
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myelomaMichael Heider, Ruth Eichner, Jacob Stroh, et al.
Nature Medicine|June 14, 2016
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicityRuth Eichner, Michael Heider, Vanesa Fernández-Sáiz, et al.
Blood Advances|August 2, 2022
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myelomaGuus J J E Heynen, Francis Baumgartner, Michael Heider, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Vaccines|August 29, 2024
Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients-A Tailored Approach Based on SARS-CoV-2 Vaccine ResponseKrischan Braitsch, Samuel D Jeske, Jacob Stroh, et al.
Molecular Cell|February 11, 2021
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myelomaMichael Heider, Ruth Eichner, Jacob Stroh, et al.
Nature Medicine|June 14, 2016
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicityRuth Eichner, Michael Heider, Vanesa Fernández-Sáiz, et al.
Blood Advances|August 2, 2022
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myelomaGuus J J E Heynen, Francis Baumgartner, Michael Heider, et al.
Pageof 2